Scott Storrer to Join Strand Life Sciences as President of North America

BANGALORE, July 10, 2014 /PRNewswire/ --

Strand Life Sciences is pleased to announce that Scott Storrer, former President and CEO of Genomind, will be joining Strand Life Sciences as President of North America.

Storrer will oversee strategy, expansion and operation of Strand Genomics Inc., the wholly-owned subsidiary of Strand Life Sciences in North America. Strand is a leader in technology innovations for personalised medicine using genomics in over 2,000 clinical and research institutions worldwide. By enhancing sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing individualised medicine to the world.

"We are excited to have Scott Storrer join our team," said Dr. Vijay Chandru, Chairman and CEO of Strand. "Storrer's 20 plus years of executive experience, leading and growing profitable businesses in the U.S. healthcare industry across payer, provider and personalised medicine sectors will help develop a strong presence for Strand in North America."

"We are thrilled to have Scott leading our team in North America. His experience in building and leading complex organisations, superb network of relationships and deep understanding of personalised medicine make him an ideal leader for Strand, as we scale up globally," said Ravi Venkatesan, Former Microsoft India Chairman and Board Member of Strand Life Sciences.

"I am honoured to join this team and help develop the North American market for Strand Life Sciences," said Storrer. "Already, more than 2000 research labs at the top clinical research, pharmaceutical and biotechnology organisations worldwide, plus, 100 hospitals and clinics have adopted Strand's genomics solutions. As Strand is lowering the cost for individualised medicine, North American markets have a huge opportunity to take advantage of Strand's successful products and services."

Storrer joins Strand from Genomind, the leading personalised medicine company providing molecular diagnostic tests in the area of behavioural health, where he served as President and CEO. In 24 months, Storrer transitioned Genomind from a start-up to growth company and secured Series A financing. Prior to Genomind, Storrer was President and CEO of MEDecision and earlier in his career Chief Operations Officer for CIGNA's Healthcare, Group Insurance and International divisions with $1.8billion operating expenses and over 17,000 employees.

Storrer received a bachelor's degree in Economics and Mathematics from DePauw University in 1989 and an MBA from Boston University in 1993.

About Strand Life Sciences  

Founded in 2000, Strand is a leader in technology innovations for healthcare using genomics. By enhancing sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing individualised medicine to the world.

Over 2,000 research labs and 100 hospitals and clinics have adopted Strand's genomics solutions. These include leading clinical research, pharmaceutical, and biotechnology organizations worldwide. Strand also has three clinical and translational research laboratories in Bangalore that are enabled with cutting edge next generation sequencing technologies. With a highly skilled interdisciplinary workforce of more than 200 computer and life scientists, Strand's product portfolio is the result of experience gained from sequencing, analysing, interpreting, and reporting on clinical samples in many clinical indications.

Strand is a portfolio company of Biomark Capital Partners, a San Francisco based global fund for health and life science, and is ranked in the top tier of NGS informatics providers by Frost & Sullivan.

For more information view Strand's video, visit http://www.strandls.com, or follow us on twitter: @StrandLife

Primary Media Contact: Preeti Goswami, [email protected], +91-9535678825, Ogilvy Public Relations

Secondary Media contact: Gregory Pappas, [email protected], +1-610-225-0350, Customedialabs